


CLAIMS






1. An imidazole derivative of formula (I) :





5

and acid addition salts and stereoisomeric forms thereof, wherein :


- R_1 and R_2 are each independently hydrogen, a (C_1-C_6) alkyl or a (C_3-C_8) cycloalkyl ; or R_1 and R_2 together form a saturated or unsaturated 5-, 6- or 7- membered carbocyclic ring;
- 10 • Q is $(CH_2)_m-X-(CH_2)_n-A$;
- A is a direct link, O, S, SO, SO_2 , NR_5 ;
 - X is a direct link, CF_2 , O, S, SO, SO_2 , C(O), NR_5 or CR_6R_7 ;
 - Z is a group selected from:



and




- m and n are each independently 0, 1, 2, 3 or 4;
- p is 1, 2, 3 or 4;
- q is 0, 1 or 2;
- the dotted line means that R₈ and/or R₉ can be on any position of the benzothiophene ring;
- R₃ and R₈ are each independently hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, OPO(OR₁₀)₂, NR₁₀R₁₁, SO₂NR₁₀R₁₁, OSO₂NR₁₀R₁₁, OSO₂OR₁₀, SO₂OR₁₀, SSO₂NR₁₀R₁₁, CF₂SO₂OR₁₀, CF₂SO₂NR₁₀R₁₁, CF₂-tetrazolyl or NR₁₂SO₂NR₁₀R₁₁, OSO₂NR₁₂SO₂NR₁₀R₁₁, CO₂R₁₀, CONR₁₀R₁₁, OCHO, OCONR₁₀R₁₁, OCSNR₁₀R₁₁, SCONR₁₀R₁₁, SCSNR₁₀R₁₁, tetrazolyl, NR₁₂CONR₁₀R₁₁, NR₁₀-CHO group;
- when Q-Z is



- 15 n is 0, 1 or 2 and p is 1, one of R₃ and R₈ is a hydroxy, nitro, OPO(OR₁₀)₂, NR₁₀R₁₁, OSO₂NR₁₀R₁₁, OSO₂OR₁₀, SO₂OR₁₀, SSO₂NR₁₀R₁₁, CF₂SO₂OR₁₀, CF₂-tetrazolyl, NR₁₂SO₂NR₁₀R₁₁, OSO₂NR₁₀SO₂NR₁₁R₁₂, CO₂R₁₀, CONR₁₀R₁₁, OCHO, OCONR₁₀R₁₁, OCSNR₁₀R₁₁, SCONR₁₀R₁₁, SCSNR₁₀R₁₁, tetrazolyl, NR₁₂CONR₁₀R₁₁, NR₁₀-CHO group and the other is hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, NR₁₀R₁₁, SO₂NR₁₀R₁₁, OSO₂NR₁₀R₁₁, OSO₂OR₁₀, SO₂OR₁₀, SSO₂NR₁₀R₁₁, CF₂SO₂OR₁₀, CF₂SO₂NR₁₀R₁₁, CF₂-tetrazolyl, NR₁₂SO₂NR₁₀R₁₁, OSO₂NR₁₂SO₂NR₁₀R₁₁, CO₂R₁₀, CONR₁₀R₁₁, OCHO, OCONR₁₀R₁₁, OCSNR₁₀R₁₁, SCONR₁₀R₁₁, SCSNR₁₀R₁₁, tetrazolyl, NR₁₂CONR₁₀R₁₁, NR₁₀-CHO group;
- 20 • R₄ and R₉ are each independently hydrogen or a hydroxy, cyano, halogen, nitro, OPO(OR₁₀)₂, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, NR₁₀R₁₁, SO₂NR₁₀R₁₁, OSO₂NR₁₀R₁₁, OSO₂OR₁₀, SO₂OR₁₀, SSO₂NR₁₀R₁₁, CF₂SO₂OR₁₀, CF₂SO₂NR₁₀R₁₁, CF₂-tetrazolyl, NR₁₂SO₂NR₁₀R₁₁, OSO₂NR₁₂SO₂NR₁₀R₁₁, CO₂R₁₀, CONR₁₀R₁₁, OCHO, OCONR₁₀R₁₁, OCSNR₁₀R₁₁, SCONR₁₀R₁₁, SCSNR₁₀R₁₁, tetrazolyl, NR₁₂CONR₁₀R₁₁, NR₁₀-CHO group;
- 25 • R₄ and R₉ are each independently hydrogen or a hydroxy, cyano, halogen, nitro, OPO(OR₁₀)₂, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, NR₁₀R₁₁, SO₂NR₁₀R₁₁, OSO₂NR₁₀R₁₁, OSO₂OR₁₀, SO₂OR₁₀,


$\text{SSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{CF}_2\text{SO}_2\text{OR}_{10}$, $\text{CF}_2\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{CF}_2\text{-tetrazolyl}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, CO_2R_{10} , CHO , $\text{CONR}_{10}\text{R}_{11}$, OCHO , $\text{OCONR}_{10}\text{R}_{11}$, $\text{OCSNR}_{10}\text{R}_{11}$, $\text{SCNR}_{10}\text{R}_{11}$, $\text{SCSNR}_{10}\text{R}_{11}$, tetrazolyl , $\text{NR}_{12}\text{CONR}_{10}\text{R}_{11}$, $\text{NR}_{10}\text{-CHO}$ group;

- 5 • when p is 2, 3 or 4 the R_9 s can be the same or different;
- R_6 and R_7 are independently hydrogen, halogen, a ($\text{C}_1\text{-C}_6$)alkyl or a ($\text{C}_3\text{-C}_8$)cycloalkyl;
- R_5 , R_{10} , R_{11} and R_{12} are each independently hydrogen, hydroxy, a ($\text{C}_1\text{-C}_6$)alkyl, or a ($\text{C}_3\text{-C}_8$)cycloalkyl; R_{10} can also be a salt; R_{10} and R_{11} can also form, 10 together with the nitrogen atom to which they are bound, a 5- to 7-membered heterocycle containing one or two heteroatoms selected from O, S and N;
- when Z is



- 15 and p is 1,
then R_8 and R_9 can also form together with the phenyl ring a benzoxathiazine dioxide, a dihydrobenzoxathiazine dioxide, a benzoxathiazinone dioxide, a benzoxathiazole dioxide, a benzodithiadiazine tetraoxide, a benzodithiazine tetraoxide or a benzodioxadithiine tetraoxide;

- 20 • when Z is



- 25 R_3 and R_4 together with the phenyl ring bearing them can also form a benzofuran or a N-methylbenzotriazole, provided that when p is 1 and Q is $(\text{CH}_2)_n$, then R_8 and R_9 are independently a hydroxy, nitro, $\text{OPO}(\text{OR}_{10})_2$, $\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{OR}_{10}$, $\text{SO}_2\text{OR}_{10}$, $\text{SSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{CF}_2\text{SO}_2\text{OR}_{10}$, $\text{CF}_2\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{CF}_2\text{-tetrazolyl}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, CO_2R_{10} ,

$\text{CONR}_{10}\text{R}_{11}$, OCHO , $\text{OCONR}_{10}\text{R}_{11}$, $\text{OCSNR}_{10}\text{R}_{11}$, $\text{SCONR}_{10}\text{R}_{11}$, $\text{SCSNR}_{10}\text{R}_{11}$, tetrazolyl, $\text{NR}_{12}\text{CONR}_{10}\text{R}_{11}$ or $\text{NR}_{10}\text{-CHO}$ group.

2. A derivative according to claim 1, and acid addition salts and
5 stereoisomeric forms thereof, wherein:

- one of R_3 and R_8 is a hydroxy, nitro, $\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$ or $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$ group; and
- the other is hydrogen or a hydroxy, cyano, halogen, nitro, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, trifluoromethyl, $(\text{C}_1\text{-C}_6)\text{alkylthio}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfonyl}$, acyl,
10 $(\text{C}_1\text{-C}_6)\text{alkoxycarbonyl}$, carboxamido, $\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$ group;

3. A derivative according to claim 1 or 2, and acid addition salts and stereoisomeric forms thereof, wherein:

- one of R_3 and R_8 is hydroxy, cyano, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ or $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$; and
- the other is hydrogen or a hydroxy, halogen, nitro, cyano, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $\text{NR}_{10}\text{R}_{11}$, $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{SO}_2\text{NR}_{11}\text{R}_{12}$ group.

20 4. A derivative according to any one of claim 1 to 3, and acid addition salts and stereoisomeric forms thereof, wherein:

- one of R_3 and R_8 is cyano; and
- the other is hydrogen or a hydroxy, halogen, nitro, $(\text{C}_1\text{-C}_6)$ alkoxy, $\text{NR}_{10}\text{R}_{11}$, $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$ group.

25 5. A derivative according to any one of claims 1 to 4, and acid addition salts and stereoisomeric forms thereof, wherein:

- R_4 and R_9 are each independently hydrogen, hydroxy, cyano, halogen, nitro, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, trifluoromethyl, $(\text{C}_1\text{-C}_6)\text{alkylthio}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfonyl}$, acyl, $(\text{C}_1\text{-C}_6)\text{alkoxycarbonyl}$, carboxamido, $\text{NR}_{10}\text{R}_{11}$, $\text{OSO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{12}\text{SO}_2\text{NR}_{10}\text{R}_{11}$, CO_2R_{10} or CHO group.

6. A derivative according to any one of claim 5, and acid addition salts and stereoisomeric forms thereof, wherein:

- one of R₄ and R₉ is hydrogen or a hydroxy, cyano or OSO₂NR₁₀R₁₁; and
- the other is hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, NR₁₀R₁₁, OSO₂NR₁₀R₁₁, CO₂R₁₀, CHO, NR₁₂SO₂NR₁₀R₁₁ group.


7. A derivative according to claim 6, and acid addition salts and stereoisomeric forms thereof, wherein:

- 10 • R₄ is hydrogen, hydroxy, cyano or OSO₂NR₁₀R₁₁;
- R₉ is a hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, NR₁₀R₁₁, OSO₂NR₁₀R₁₁, CO₂R₁₀, CHO group.

8. A derivative according to claim 7, and acid addition salts and stereoisomeric forms thereof, wherein:

- 15 • R₄ is hydrogen; and
- R₉ is hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, NR₁₀R₁₁, OSO₂NR₁₀R₁₁, CO₂R₁₀, CHO or NR₁₂SO₂NR₁₀R₁₁.

- 20 9. A derivative according to any one of claims 1 to 8, and acid addition salts and stereoisomeric forms thereof, wherein Z is:



in which:


- 25 • R₈ is hydrogen, hydroxy, halogen, nitro, cyano, (C₁-C₆)alkoxy, NR₁₀R₁₁, SO₂NR₁₀R₁₁, OSO₂NR₁₀R₁₁, NR₁₂SO₂NR₁₀R₁₁ or OSO₂NR₁₀SO₂NR₁₁R₁₂ group;
- R₉ hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, NR₁₀R₁₁, OSO₂NR₁₀R₁₁, CO₂R₁₀, CHO, NR₁₂SO₂NR₁₀R₁₁ group;
- p and q are as defined in claim 1.

10. A derivative according to any one of claims 1 to 9, and acid addition salts and stereoisomeric forms thereof, wherein Q is selected from a direct link, C(O), SO₂, CONH, C(O)(CH₂)_n, (CH₂)_n(O) or (CH₂)_n in which n is 0,1 or 2.

5

11. A derivative according to claim 1, and acid addition salts and stereoisomeric forms thereof, wherein:

- Z is



10

- Q is (CH₂)_n in which n is 0,1 or 2;
- one of R₃ and R₈ is a hydroxy, nitro, NR₁₀R₁₁, OSO₂NR₁₀R₁₁ or NR₁₂SO₂NR₁₀R₁₁ group and the other is hydrogen or a hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio,

15

(C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, NR₁₀R₁₁, OSO₂NR₁₀R₁₁ or NR₁₂SO₂NR₁₀R₁₁ group;

- R₄ and R₉ are each independently hydrogen, hydroxy, cyano, halogen, nitro, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfonyl, acyl, (C₁-C₆)alkoxycarbonyl, carboxamido, NR₁₀R₁₁,

20


OSO₂NR₁₀R₁₁ or NR₁₂SO₂NR₁₀R₁₁ group .

- R₁₀ and R₁₁ are each independently hydrogen, a (C₁-C₆)alkyl or a (C₃-C₈)cycloalkyl;
- p is 1, 2, 3 or 4;
- R₈ and R₉ together with the phenyl ring bearing them can also form a benzoxathiazine dioxide or a dihydrobenzoxathiazine dioxide;
- R₃ and R₄ together with the phenyl ring bearing them can also form a benzofuran or a N-methylbenzotriazole.

12. A derivative according to claim 11, and acid addition salts and

30 stereoisomeric forms thereof, wherein:

- Z is



- Q is $(CH_2)_n$ in which n 0, 1 or 2;
- R_8 is hydroxy, halogen, nitro, cyano or a (C_1-C_6) alkoxy, $NR_{10}R_{11}$, $SO_2NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$, or $NR_{12}SO_2NR_{10}R_{11}$ group;
- R_9 is hydrogen, hydroxy, cyano, halogen, nitro, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, trifluoromethyl, $NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$;
- p is as defined in claim 1.

10 13. A derivative according to claim 12, and acid addition salts and stereoisomeric forms thereof, wherein:

- n is 0 or 1;
- R_4 and R_9 are each independently hydrogen, halogen, (C_1-C_6) alkoxy, acyl, $NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$ or $NR_{12}SO_2NR_{10}R_{11}$.

15

14. A derivative according to any one of claims 11 to 13, and acid addition salts and stereoisomeric forms thereof, wherein:

- n is 0 or 1;
- R_1 , R_2 and R_4 are each hydrogen;
- R_9 is hydrogen, halogen, (C_1-C_6) alkyl or $OSO_2NR_{10}R_{11}$.

15. A derivative according to any one of claims 11 to 14, and acid addition salts and stereoisomeric forms thereof, wherein:

- n and p are 1;
- 25 • R_8 is a hydroxy, halogen, nitro, cyano, (C_1-C_6) alkoxy, $NR_{10}R_{11}$, $SO_2NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$, $NR_{12}SO_2NR_{10}R_{11}$ or $OSO_2NR_{10}SO_2NR_{11}R_{12}$ group;
- R_9 a hydroxy, cyano, halogen, nitro, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, trifluoromethyl, $NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$, CO_2R_{10} or CHO group;
- R_3 is cyano, hydroxy, $OSO_2NR_{10}R_{11}$ or $NR_{12}SO_2NR_{10}R_{11}$;
- 30 • R_4 is hydrogen, hydroxy, halogen, cyano or $OSO_2NR_{10}R_{11}$.


16 A derivative according to any one of claims 12 to 15, and acid addition salts and stereoisomeric forms thereof, wherein one of R_3 and R_8 is hydroxy, cyano or $OSO_2NR_{10}R_{11}$ and the other is hydroxy, nitro, $NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$ or
5 $NR_{12}SO_2NR_{10}R_{11}$.

17 A derivative according to claim 16, and acid addition salts and stereoisomeric forms thereof, wherein one of R_3 and R_8 is cyano or $OSO_2NR_{10}R_{11}$ and the other is hydroxy or $OSO_2NR_{10}R_{11}$.

10

18 A derivative according to claims 1 or 2, and acid addition salts and stereoisomeric forms thereof, wherein :

- Z is



15 in which:

- Q is $(CH_2)_m-X-(CH_2)_n-A-$;
- A is a direct bond or O, S, SO, SO_2 , NR_5 ;
- X is a direct bond, CF_2 , O, S, SO, SO_2 , C(O), NR_5 or CR_6R_7 ;
- m and n are each independently 0, 1, 2, 3 or 4;
- 20 • R_3 , R_4 , R_8 and R_9 are each independently hydrogen or a hydroxy, cyano, halogen, nitro, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, benzyloxy, trifluoromethyl, (C_1-C_6) alkylthio, (C_1-C_6) alkylsulfonyl, acyl, (C_1-C_6) alkoxycarbonyl, $NR_{10}R_{11}$, $OPO(OR_{10})_2$, $OCHO$, $COOR_{10}$, $SO_2NR_{10}R_{11}$, $OSO_2NR_{10}R_{11}$, SO_2OR_{10} , OSO_2OR_{10} , $SSO_2NR_{10}R_{11}$, $CONR_{10}R_{11}$, $OCONR_{10}R_{11}$, $OCSNR_{10}R_{11}$, $SCONR_{10}R_{11}$,
25 $SCSNR_{10}R_{11}$, $NR_{12}SO_2NR_{10}R_{11}$, tetrazolyl, $NR_{10}CONR_{11}OH$, $NR_{10}SO_2NR_{11}OH$, $NOH-CHO$, $NOHSO_2NR_{10}R_{11}$ or $OSO_2NR_{10}OH$ group;
- p is 0, 1 or 2.
- R_5 , R_6 , R_7 , R_{10} , R_{11} and R_{12} are each independently hydrogen, a (C_1-C_6) alkyl or a (C_3-C_8) cycloalkyl; R_{10} can also be a salt; R_{10} and R_{11} can also form,

together with the nitrogen atom to which they are bound, a 5- to 7-membered heterocycle containing one or two heteroatoms selected from O, S and N;

- The dotted line means that Q and/or R₈ and/or R₉ can be on any position of the benzothiophene ring.
- 5 19 A derivative according to claim 18, and acid addition salts and stereoisomeric forms thereof, wherein R₈ is OSO₂NR₁₀R₁₁ or NR₁₂SO₂NR₁₀R₁₁.
- 10 20 A derivative according to claim 18 or 19, wherein R₉ is hydrogen, halogen, nitro, COOR₁₀ or cyano.
- 15 21 A derivative according to any one of claims 18 to 20, wherein R₄ is hydrogen, halogen, cyano, (C₁-C₆)alkoxy, NR₁₀R₁₁, OSO₂NR₁₀R₁₁ or NR₁₂SO₂NR₁₀R₁₁
- 22 22 A derivative according to any one of claims 18 to 21, wherein R₁₀, R₁₁ and R₁₂ are each independently hydrogen or (C₁-C₆)alkyl.
- 20 23 A derivative according to any one of claims 18 to 22, wherein Q is (CH₂)_m-X-(CH₂)_n-A where m is 0, 1 or 2 and X is a direct bond, SO₂ or CO, n is 0 and A is a direct bond.
- 25 24 A derivative according to any one of claims 18 to 23, wherein R₃ is hydrogen, halogen or cyano.
- 25 25 A derivative according to claim 1 or 2, and acid addition salts and stereoisomeric forms thereof, wherein :
- Z is a group:
- The diagram shows a benzothiophene ring (a six-membered aromatic heterocyclic compound with a sulfur atom at the 2-position). A substituent group R₈ is shown at the top position of the ring. Another substituent group (R₉)_p is shown attached to the ring, positioned between the 2 and 5 positions relative to R₈.
- 30 in which R₈, R₉ and p are as defined in claim 1.

26 A derivative according to claim 25, and acid addition salts and stereoisomeric forms thereof, wherein :

- R₃ is cyano or OSO₂NR₁₀R₁₁;
- R₄ is hydrogen, hydroxyl, halogen, cyano, OSO₂NR₁₀R₁₁;
- R₈ is hydroxy, cyano, OSO₂NR₁₀R₁₁, NR₁₀R₁₁, NR₁₂SO₂NR₁₀R₁₁, OCHO or tetrazolyl;
- R₉ is hydrogen, halogen, nitro, cyano or CO₂R₁₀; and
- Q is as defined in claim 10.

10

27. A derivative according to any one of claims 1 to 26, and acid addition salts and stereoisomeric forms thereof, wherein R₁ and R₂ are independently hydrogen or a (C₁-C₆)alkyl group.

15 28 A derivative according to any one of claims 1 to 27, and acid addition salts and stereoisomeric forms thereof, wherein R₁₀ and R₁₁ are hydrogen.

29 A compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance.

20

30 A pharmaceutical composition comprising a derivative according to any one of claims 1 to 28, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier.

25 31 The pharmaceutical composition according to claim 30, comprising from 0.1 to 400 mg of said derivative.

32 Use of a derivative according to anyone of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment or prevention of hormone- or non hormone-dependent tumors, wherein said derivative is optionally combined with a sexual endocrine therapeutic agent.

- 33 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the control or management of reproductive functions, wherein said derivative is optionally combined with a LH-RH agonist or antagonist, an estroprogestative contraceptive, a progestin, an anti-progestin or a prostaglandin.
- 5
- 34 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment or prevention of benign or malignant diseases of the breast, the uterus or the ovary, wherein said derivative is optionally combined with an antiandrogen, an anti-estrogen, a progestin or a LH-RH agonist or antagonist.
- 10
- 15 35 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment or prevention of androgen-dependent diseases or benign or malignant diseases of the prostate or the testis, wherein said derivative is optionally combined with an antiandrogen, a progestin, a lyase inhibitor or a 20 LH-RH agonist or antagonist.
- 20
- 36 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment or prevention of cognitive function disorders, especially senile dementia, in particular Alzheimer's disease.
- 25
- 37 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a medicament for the treatment or prevention of immunodisorders.
- 30
- 38 Use of a derivative according to any one of claims 1 to 28 or a pharmaceutically acceptable acid addition salt thereof in the manufacture of a

medicament for the treatment or prevention of pathologies in which inhibition of aromatase and/or steroid sulfatase and/or carbonic anhydrase is required.

39 A method of treating a disease in which aromatase and/or steroid
5 sulfatase and/or carbonic anhydrase is involved, which comprises administering
to a subject in need thereof a therapeutically effective amount of a compound
according to any one of claims 1 to 28.